Nearly 20% of human cancers worldwide have an infectious etiology with the most prominent examples being hepatitis B and C virus-associated hepatocellular carcinoma and human papilloma virus-associated cervical cancer. There is an urgent need to find new approaches to treatment and prevention of virus-associated cancers.
Viral antigens have not been previously considered as targets for treatment or prevention of virus-associated cancers. We hypothesized that it was possible to treat experimental HPV16-associated cervical cancer (CC) and Hepatitis B-associated hepatocellular carcinoma (HCC) by targeting viral antigens expressed on cancer cells with radiolabeled antibodies to viral antigens. Treatment of experimental CC and HCC tumors with 188Re-labeled mAbs to E6 and HBx viral proteins, respectively, resulted in significant and dose-dependent retardation of tumor growth in comparison with untreated mice or mice treated with unlabeled antibodies.
This strategy is fundamentally different from the prior uses of radioimmunotherapy in oncology, which targeted tumor-associated human antigens and promises increased specificity and minimal toxicity of treatment. It also raises an exciting possibility to prevent virus-associated cancers in chronically infected patients by eliminating cells infected with oncogenic viruses before they transform into cancer.
Citation: Wang XG, Revskaya E, Bryan RA, Strickler HD, Burk RD, Casadevall A, et al. (2007) Treating Cancer as an Infectious Disease—Viral Antigens as Novel Targets for Treatment and Potential Prevention of Tumors of Viral Etiology. PLoS ONE 2(10): e1114. https://doi.org/10.1371/journal.pone.0001114
Academic Editor: Mikhail Blagosklonny, Ordway Research Institute, United States of America
Received: October 5, 2007; Accepted: October 10, 2007; Published: October 31, 2007
Copyright: © 2007 Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: E. Dadachova is supported by the NIH grant AI60507; A. Casadevall - by the NIH grants AI33774, AI33142, AI52733, HL59842, and U54 AI157158; R.D. Burk by the NIH grant CA078527. This work was supported in part by the Albert Einstein College of Medicine Comprehensive Cancer Center and the Center for AIDS Research at the Albert Einstein College of Medicine and Montefiore Medical Center funded by the National Institutes of Health (NIH AI-51519).
Competing interests: Patent application for this technology has been filed with US PTO
It has been estimated that nearly 20% of human cancers worldwide have an infectious etiology . Most of these tumors are of viral origin, and include firmly established associations of hepatitis B virus (HBV) and hepatitis C virus (HCV) with hepatocellular carcinoma; and of human papillomavirus (HPV)-with cancers of the cervix, anus, vulva, vagina; as well as associations of oropharynx Epstein-Barr virus (EBV) with lymphoma and nasopharyngeal carcinoma; human T lymphotropic virus type 1 (HTLV-1)-with adult T-cell leukemia/lymphoma, and human herpes virus 8 (HHV-8)-with Kaposi sarcoma –. In combination, these virus-associated tumors represent a burden of approximately 1.3 million cases of cancer each year, with HBV/HCV-associated liver cancer accounting for 523,000 cases, and HPV-associated tumors accounting for 561,000 cases . The need to find new approaches to the treatment and prevention of virus-associated cancers is obvious and urgent.
Radioimmunotherapy (RIT) utilizes antigen-antibody binding to deliver cytotoxic doses of particulate radiation to tumor cells , . RIT, for example, has been used to successfully treat refractory and recurrent lymphomas, with two radiolabeled monoclonal antibodies (mAb) targeted against CD20 (Zevalin® and Bexxar®) having received FDA approval for this purpose. It is likely, in fact, that RIT will become a first line treatment for follicular lymphoma . This “traditional” cancer RIT targets “self” antigens. Recently, we demonstrated that RIT has also broad potential for the treatment of fungal and bacterial infections through targeting of microbial antigens with radiolabeled mAbs in experimental models of fungal and bacterial infections , [reviewed in 13]. In addition, we found that HIV-1 infected cells could be eliminated in vitro and in vivo by targeting gp120 and gp41 viral glycoproteins expressed on the surface of infected cells with radiolabeled viral protein-specific mAbs .
We hypothesized that RIT targeted against viral antigens could be used in the treatment of a broad range of viral infectious diseases and virus-associated tumors , . Many virus-associated cancers express viral antigens either internally or on their surfaces. It is important to note that even viral antigens expressed intracellularly are potential targets for RIT, since tumor cell turnover is likely to result in the release of these proteins into the interstitial space of the tumor. This approach is fundamentally different from the previously described uses of RIT which target tumor-associated antigens that are “self” (i.e., human) proteins. By targeting viral and not “self” proteins, it is hoped that radiolabeled mAbs can be more specifically concentrated within tumor tissue, resulting in greater efficacy and less toxicity. Here we describe the proof-of-principle experiments aimed at demonstrating the feasibility of treating experimental HPV16-associated cervical cancer (CC) and Hepatitis B-associated hepatocellular carcinoma (HCC) by targeting viral antigens expressed on cancer cells with radiolabeled antibodies to viral antigens.
Selection of a cell line-antigen combination to act as an experimental cervical cancer (CC) model
To evaluate the potential of RIT to target viral antigens in cancers of viral etiology, we needed to identify tumor cell lines that expressed the target antigen and could also be implanted into nude mice. We selected HPV16 and HPV18 cell lines, since these two HPV types account for approximately 70% of cervical cancers and a significant fraction of head and neck tumors , . The E6 and E7 oncoproteins were considered the best potential antigenic targets, since these proteins are expressed in essentially all cervical cancer cells, whereas other viral genes may be lost. Mutational analysis has shown that the E6 and E7 viral oncoproteins are necessary and sufficient for the immortalization of human cells by HPV. Therefore, we assessed by Western blot the expression of E6 and E7 in three human cervical carcinoma cell lines–HPV16-positive CasKi and SiHa cell lines and HPV18-positive HeLa S3 cell line. While CasKi cells expressed both E6 and E7 antigens (Fig. 1a, b), SiHa and HeLa S3 cell lines had no measurable expression of E6 antigen (results not shown) but did express E7 protein (Fig. 1d, e); albeit, the level of E7 expression was low in SiHa cells (Fig. 1d).
a) E6 from protein extracts of CasKi cells treated with MG132 for 3 hrs; b) E7 from protein extracts of CasKi cells treated with MG132 for 3 hrs; c) E6 from protein extracts of CasKi cells treated with MG132 for 6 hrs; d) E7 from protein extracts of SiHa cells treated with MG132 for 3 hrs; e) E7 from protein extracts of HeLa S3 cells treated with MG132 for 3 hrs; f) HBX from protein extracts of Hep 3B2.1-7 cells treated with MG132 for 3 hrs.
The proteasome inhibitor MG132 reduces the degradation of ubiquitin-conjugated proteins in mammalian cells without affecting ATPase or isopeptidase activities. MG132 has been reported to result in increased levels of E6 and E7 proteins in cervical cancer cells , . As higher amounts of target antigens can potentially improve RIT results, we investigated the influence of pre-treatment of CC cells with proteasome inhibitor MG132 on the levels of E6 and E7 expression. Fig. 1a and b shows that in CasKi cells pre-treatment with MG132 caused an increase in expression of both E6 and E7, with the greatest level of expression achieved with use of 2 and 5 µg/mL of MG132 which subsided when higher doses were used. Prolongation of the incubation period of CasKi cells with MG132 did not result in greater E6 expression. In fact, we observed decreased E6 expression with prolonged CasKi cell exposure to MG132 (Fig. 1c), which might reflect an increase of protein degradation after more than 3 hr of incubation. Similar experiments were performed for E7 protein in SiHa and HeLa S3 cell lines (Fig. 1d,e). SiHa cells did not demonstrate an appreciable increase in the E7 levels (Fig. 2d); whereas, E7 levels did increase slightly for HeLa S3 cells treated with 1 and 2 µg/mL MG132 (Fig. 1e). Given reliable and high expression of E6 in CasKi cells as well as their ability to produce tumors in nude mice-we selected CasKi cells and E6 protein for further in vitro and in vivo experiments.
a, b) immunofluorescence of fixed and permeabilized tumor cells. Left panels show light microscopy images of the cells. Heavily damaged cells are marked with arrows. Right panels show immunofluorescent images of the same slides treated with viral protein-specific mAbs followed by FTIC-conjugated polyclonal antibody to mouse IgGs: a–CasKi cells and E6-specific C1P5 mAb, b-Hep 3B2.1-7 cells and HBx-specific 4H9 mAb; c) immunohistochemistry of CasKi tumors. Left panel shows binding of E6-specific mAb C1P5. Right panel shows absence of binding of control mAb 18B7; d) western blot of Hep 3B2.1-7 tumor with HBx-specific mAb 4H9.
Selection of a cell line-antigen combination to act as an experimental Hepatitis B-associated hepatocellular carcinoma (HCC) model
We evaluated two Hepatitis B-associated viral proteins as potential targets for RIT-HBx and PreS2. HBx is suspected to have a role in hepatocarcinogenesis and, unlike other potential choices, HBx has no homology to host proteins. Further, the gene that codes for HBx is retained even when the HBV genome becomes integrated in HCC, whereas other HBV genes may be lost , . PreS2 is also suspected to have a role in hepatocarcinogenesis (i.e., through transactivation of cellular genes important in growth control) . HBx protein was consistently detected by Western blot of HCC cell line Hep 3B2.1-7 using 4H9 mAb, and its expression was independent of pre-treatment with MG132 proteasome inhibitor (Fig. 1f), whereas preS2 was not detected (results not shown). Therefore, we selected the Hep 3B2.1-7 cell line and HBx protein combination for further experiments.
Binding of antibodies to viral antigens in non-viable cells
To find out if antibodies to viral proteins which were identified as targets for RIT will be able to bind to viral proteins in non-viable tumor cells, we performed immunofluorescence of fixed and permeabilized CasKi and Hep 3B2.1-7 cells with mAbs C1P5 to E6 and 4H9 to HBx proteins, respectively, followed by FITC-conjugated polyclonal antibody to mouse IgG. While the binding of C1P5 mAb to the cells which were almost intact was weak, the heavily damaged cells with penetrable membranes showed bright fluorescence pointing to binding of C1P5 to E6 (Fig. 2a). The fixation and permeabilization also made possible for mAb 4H9 to bind to HBx protein (Fig. 2b). No binding of control IgG1 mAb to fixed and permeabilized CasKi or Hep 3B2. 1-7 cells was observed (results not shown).
Expression of viral proteins in the tumors
To confirm that CasKi and Hep 3B2.1-7 cells continued to express E6 and HBx viral antigens, respectively, in the tumors induced in nude mice, we performed immunohistochemistry and immunoblot for E6 and HBx, respectively. Western blot was chosen for Hep 3B2.1-7-induced tumors based on the literature reporting difficulties in reliably detecting HBx protein in organs by immunohistochemistry . There was intense staining of E6 with specific mAb C1P5 in CasKi tumors (Fig. 2c, left panel) with no staining observed with control IgG1 mAb (Fig. 2c, right panel). Western blot of Hep 3B2.1-7-induced tumors revealed the presence of HBx protein (Fig. 2d). Thus, the presence of the target viral proteins in CC and HCC experimental tumors provided the possibility of targeting these antigens in vivo with radiolabeled mAbs for scintigraphic imaging and therapy.
Biodistribution of radiolabeled mAbs to viral proteins in CasKi and Hep 3B2.1-7-tumor bearing nude mice
We performed imaging and biodistribution experiments with 188Re-radiolabeled C1P5 and 4H9 mAbs in CasKi and Hep 3B2.1-7-tumor bearing nude mice, respectively, to ascertain the localization of mAbs to the tumors. At 24 hr post-injection the CasKi tumor was visible on the scintigraphic image of a mouse injected with 188Re-C1P5 mAb (Fig. 3a) as opposed to the image of a mouse injected with irrelevant 188Re-18B7 mAb (Fig. 3b). We also calculated the tumor to muscle ratio from the 48 hr biodistribution results which was 10∶1 for 188Re-C1P5 versus 3∶1 for 188Re-18B7. The overall uptake of 188Re-C1P5 mAb in the tumors at 48 hr post-injection was 2.0(±0.3)% of the injected dose per gram tumor. Other organs like liver, spleen and blood showed the levels of uptake characteristic of IgG1 mAbs. For Hep 3B2.1-7 we utilized another approach to prove the specificity of mAb uptake in the tumor by using a model when a mouse carries two different tumors–one the tumor of interest and another–irrelevant control tumor. Nude mice carried A2058 human metastatic melanoma tumor on the right flank and Hep 3B2.1-7 on the left (Fig. 3c). The mice were injected with 188Re-4H9 mAb and imaged scintigraphically at 24 hr post-injection. The antibody localized to the Hep 3B2.1-7 tumor as opposed to the irrelevant control melanoma tumor (Fig. 3d). The ability of radiolabeled mAbs to viral antigens to localize to these tumors in mice justified an assessment of RIT in these in vivo cancer models.
RIT of CasKi and Hep 3B2.1-7-tumor bearing nude mice
To evaluate the therapeutic effect of 188Re-C1P5 mAb in CasKi tumor-bearing mice, the animals were injected with either 350 µCi 188Re-C1P5 mAb, or matching amounts (30 µg per mouse) of unlabeled (“cold”) C1P5 mAb or left untreated. Fig. 4a shows the change in tumor volume in the treated and control groups. RIT with 350 µCi 188Re-C1P5 mAb completely arrested tumor growth and resulted in its volume reduction (Fig. 4a and b), while untreated tumors grew aggressively (Fig. 4a and c) and untreated control mice had to be sacrificed on Day 20 post-treatment (P<<0.01). Interestingly, administration of “cold” C1P5 mAb also resulted in significant retardation of the tumor growth, which can be due to the induction of inflammation and complement cascades by the mAb.
a) changes in tumor volume; b) mouse treated with 350 µCi 188Re-C1P5 mAb; c) control mouse (both mice shown on Day 20 post-treatment).
For RIT of Hep 3B2.1-7 tumors in nude mice we initially employed the same experimental design as for CasKi tumors by using 350 µCi 188Re-4H9 mAb, “cold” mAb-treated controls and untreated groups. Administration of 350 µCi 188Re-4H9 mAb resulted in slower tumor growth but did not arrest it like in case of CasKi tumors. “Cold” 4H9 mAb did not have an effect on the tumor growth. To find the most efficient dose of radiolabeled mAb for retarding the growth of very aggressive Hep 3B2.1-7 a dose response experiment was done. The therapeutic effect of 188Re-4H9 mAb began to manifest itself at a dose of 280 µCi and the effect increased with every subsequent increase in the dose (Fig. 5a) (P<0.02). At the completion of the experiment the tumors from the control untreated mice and mice in the highest 600 µCi group were analyzed histologically. The control tumor consisted of moderately differentiated hepatoid cells with scattered small foci of necrosis, fibrin thrombosis, and hemorrhage. Neoplastic cells had ample eosinophilic to finely vacuolated cytoplasm and medium-sized nuclei to very large and anaplastic nuclei containing multiple large eosinophilic nucleoli with multinucleated cells occasionally evident. The mitotic index was high and there were scattered apoptotic cells (Fig. 5b). In contrast, the RIT-treated tumors had significantly more necrosis and hemorrhage than seen in the controls. The morphologic appearance of the tumor cells often had a more vacuolated cytoplasm suggesting degeneration (Fig. 5c).
We performed proof-of-principle in vitro and in vivo experiments to establish the feasibility of targeting viral antigens in tumors of viral etiology with radiolabeled antibodies for therapy. To this end, we studied experimental cervical carcinoma (CC) and hepatocellular carcinoma (HCC) models, since these cancers are etiologically related to HPV and HBV/HCV, respectively, and have major public health implications world-wide.
The first challenge was the choice of target viral antigens in CC and HCC. In HPV-associated CC we identified E6 and E7 oncoproteins as potential targets for RIT, because they are thought to be expressed in all cervical cancer cells; whereas, other viral genes may be lost during the multi-stage process of tumorigenesis. Similarly, in HCC, HBx expression is thought to be maintained. There is, however, an important concern in targeting these three proteins with radiolabeled mAbs–their subcellular location. Both E6 and E7 are located within the nucleus, and HBx is found in the nucleus and occasionally in the cytoplasm. As a consequence, the radiolabeled mAbs to these proteins can bind only to their respective antigens when they are released from the dead cells or when tumor cells are permeabilized. To conduct these experiments, we chose the CasKi cell line as a CC model, since we found it expressed E6 and E7 at high levels in vitro and the tumors grew aggressively in nude mice after the latent period. The Hep 3B2.1-7 cell line was chosen as a HCC model, after we observed that it expressed HBx at high levels and displayed fast tumor growth in mice.
The immunofluorescence of the tumor cells and immunohistochemistry and Western blot of the tumors revealed ample amounts of E6 and HBx antigenic targets in CasKi- and Hep 3B2.1-7-induced tumors, respectively (Fig. 2). The presence of accessible antigen for the radiolabeled mAbs is probably a result of protein release from tumor cells undergoing rapid turnover. Consequently, the radiolabeled antibodies accumulated in the tumor tissue such that they could be imaged scintigraphically (Fig. 3). One of the advantages of targeting viral antigens in the tumors that they are only found in malignant cells. In contrast, Chen and colleagues observed no differences in the tumor uptake for both specific and non-specific radiolabeled antibodies in their biodistribution experiments when they targeted intranuclear histones .
The ability of radiolabeled mAbs against viral proteins to deliver cytotoxic radionuclide 188-Rhenium to the tumor cells facilitated the successful outcomes of RIT with these mAbs in tumor-bearing mice. The administration of 350 µCi dose of E6-binding 188Re-C1P5 mAb to CasKi tumor-bearing mice completely stopped tumor growth and even resulted in its regression (Fig. 4). It is also likely that there was some added therapeutic benefit from the antibody itself as unlabeled antibodies can mediate inflammatory reactions and activate compliment. In the future, it will be worthwhile to investigate whether increased cellular levels of E6 and E7 oncoproteins could be obtained with pretreatment use of MG132 in vivo, and whether this results in a therapeutic benefit. The dose response experiments in mice bearing Hep 3B2.1-7 HCC-tumors clearly demonstrated a dose dependence for the therapeutic effect (Fig. 5). The fact that higher doses of radiolabeled mAb were needed to produce a therapeutic effect in HCC than in cervical tumor might reflect the aggressiveness of Hep 3B2.1-7 and the known radioresistance of liver tumors in comparison to the relatively radiosensitive cervical carcinomas . It is also noteworthy that therapeutic gains in both experimental tumors were achieved with doses of radioactivity that are well below the maximum tolerated dose of approximately 800 µCi for 188Re-labeled IgG1s in mice , and as such the doses used were not expected to produce any short- or long-term toxicities.
It is important to emphasize that when treating viral-associated cancers by targeting viral antigen not every cell in the tumor needs to express viral antigens for a therapeutic effect. Long range emitters such as 188Re (emission range in tissue 10 mm) emit radiation in a 360° sphere and consequently can kill cells in the vicinity of the antigen location. Furthermore, a high concentration of the targeted viral antigen is probably not required for the delivery of a therapeutic dose to the tumor, according to our recent model of RIT for melanoma (targeted against melanin which is also an intracellular antigen). This model showed that the radiation dose delivered to the tumor is largely independent of melanin (antigen) concentration .
This approach also holds the promise to prevent viral-associated cancers in chronically infected individuals-for example, persistence of HPV infection in HIV-infected individuals puts them at significant risk of developing HPV-associated cancers. While there is immunotherapy for HBV and HCV, many patients do not achieve viral clearance and the treatment is associated with substantial morbidity. There is also no vaccine for HCV, and many millions of people worldwide are infected with HBV despite the availability of an effective vaccine. Cells persistently infected with HPV, HBV, HCV or other viruses could potentially be eliminated with RIT targeted to viral antigens before they transform into malignant phenotype.
In conclusion, we performed in vitro and in vivo experiments to assess a novel strategy to treat virus associated tumors using radiolabeled mAbs targeted against viral proteins. This strategy is fundamentally different from prior uses of RIT in oncology that target tumor-associated human antigens thus resulting in significant uptake of radioactive antibody in normal tissues, leading to toxicity. The results of our study suggest that by targeting instead viral and not self-proteins it may be possible for radiolabeled mAbs to concentrate more specifically within tumor tissue, resulting in greater efficacy and less toxicity. This strategy also raises an exciting additional possibility to prevent virus-associated cancers in chronically infected patients by eliminating cells infected with oncogenic viruses before they transform into cancer.
Mouse mAbs from Abcam C1P5 to HPV16 E6+HPV18 E6 and TVG 701Y to HPV16 E7 were used in CC experiments. Mouse mAb 4H9 to HBV HBx (Aviva, Cat# AVAMM2005) and mouse mAb S26 to HBV protein Hbs (Gene Tex Inc. Cat# GTX18797) which cross-reacts with HBsAg preS2 antigen were used in HCC experiments. Murine 18B7 mAb (IgG1) to C. neoformans  was used as an irrelevant control for all specific antibodies. Rabbit polyclonal antibody conjugated with alkaline phosphatase to mouse IgG H&L was purchased from Abcam and used as secondary antibody in Western blot.
Cell lines and cell cultivation
Three human cervical carcinoma cell lines: Hela S3, SiHa and CasKi were purchased from ATCC (Manassas, VA). Cells were grown routinely in DMEM/HAM F-12K (Sigma, 1∶1) containing 10% FBS (Sigma) and 1% Penicillin-streptomycin solution (Sigma, penicillin 10,000 U and streptomycin 10 mg/ml) at 37°C in 5% CO2 incubator. The cell line Hep 3B2.1-7 (Homo sapiens hepatatocellular carcinoma) was purchased from ATCC. It contains an integrated hepatitis B virus genome and was derived from the hepatocellular carcinoma tissue of 8-year old black boy. Cells were grown routinely in Eagle's Minimum Essential Medium (EMEM) (ATCC) containing 10% FBS (Sigma) at 37°C in 5% CO2 incubator. Cell layers in 75 ml flask was dispersed by adding 2 ml 1× Trypsin-EDTA solution (Sigma, 0.25% (w/v) trypsin−0.53 mM EDTA) at room temperature for 15 minutes. A2058 cell line derived from a lymph node metastasis from patient with malignant melanoma was obtained from ATCC. The cells were maintained as monolayers in Dulbecco's Modified Eagle's Medium with 4 mM L-Glutamine, 4.5 g/L glucose, 1.5 g/L sodium bicarbonate, supplemented with 10% fetal bovine serum and 5% penicillin-streptomycin solution at 37°C and 5% CO2, and harvested by using 0.25% (w/v) Trypsin-EDTA solution. Routine maintenance of all cell lines was performed according to the ATCC protocols.
Cell pellets were suspended in the lysis buffer (4% SDS, 20% glycerol, 0.5 M TrisHCl (pH 6.8), 0.002% bromophenol blue and 10% β−mercaptoethanol). Protein samples were boiled in water for 15 min before running SDS-PAGE. Twenty five-thirty µl protein solution was loaded into each well of 12% precast SDS-PAGE gel (Bio-Rad). SDS-PAGE was used to monitor the relative protein amounts in the samples. Twelve percent SDS-PAGE gel was used to separate proteins, and electrophoresis was performed using Mini-Protean® 3 Cell system (Bio-Rad). After electrophoresis, the gel was transferred into the PVDF transfer buffer (25 mM Tris, 190 mM glycine and 2.5% (v/v) methanol) for 5 min. Then, proteins were transferred from the gel to the Immun-Blot™ PVDF membrane (Bio-Rad) on Semi-dry Electrophoretic Transfer Cell (Bio-Rad) at 15 V for 17 min. The membrane was soaked in the blocking buffer (25 mM TrisHCl (pH7.6), 1 mM EDTA and 150 mM NaCl) for 5 min, and then transferred into the blocking solution (5% non-fat dry milk in the blocking buffer), shaking gently for an hour. The membrane was incubated in TBST solution (0.1% Tween-20, 25 mM TrisHCl (pH7.6) and 500 mM NaCl) containing 1∶3000 diluted primary antibody at room temperature for 1 hour with gentle shaking. Then, the membrane was washed with TBST three times (10 min per wash). The membrane was hybridized by the secondary antibody conjugated with alkaline phosphatase (Rabbit polyclonal to mouse IgG H&L (alkaline phosphatase)) in TBST with a 1∶100,000 dilution. After three washes with TBST, the membrane was incubated in CDP-Star™ chemiluminescent substrate solution (Sigma) for 5 min, and then exposed to CL-XPosure™ film (Pierce). The film was developed as per manufacturer's instructions.
MG132 treatment of cells
MG132 (Z-LLL-CHO, MW = 457.6) purchased from CALBIOCHEM is a potent, reversible and cell-permeable proteasome inhibitor (Ki = 4 nM). MG132 was first dissolved in a drop of 100% ethanol followed by DMEM/HAM F-12K medium without addition of FBS, and the stock solution was stored at 4°C. Cell culture was harvested and transferred into 6 sterile test tubes. Each tube contained 0.5–1 ml cell culture (cell concentration was ∼106 cells/ml), and cells were allowed to grow at 37°C in 5% CO2 incubator overnight. Then, MG132 solution was added to the tubes for the final concentrations of 0, 1, 2, 5, 10 or 25 µg/ml (0, 2.1, 4.2, 10.5, 21 or 52 µM, respectively). The cells were incubated under the same conditions for another 3 or 6 hours. Finally, cells were harvested by centrifugation and clarified by washing with PBS.
Radioisotope and radiolabeling of the antibodies
The beta-emitter 188Re with a half life of 16.9 hours was eluted in the form of sodium perrhenate Na188ReO4 from an 188W/188Re generator (Oak Ridge National Laboratory, Oak Ridge, TN). Antibodies were labeled with 188Re directly through binding of reduced 188Re to the generated−SH group on the antibodies as previously described .
Immunofluorescent detection of viral antigens in tumor cells
The tumor cells were grown in the slide chambers at 37°C for 12 hrs. The medium was removed and the cells were washed with PBS three times. Throughout the procedure, the cells were washed 3 times with PBS after each treatment. They were fixed with 4% paraformaldehyde at room temperature for 20 min followed by permeabilization with 0.3% Triton-X100 in PBS at room temperature for 10 min. Fixed and permeabilized cells were blocked with 5% BSA plus 0.1% Triton X-100 in PBS at room temperature for 30 min. Viral antigens-specific mAbs were diluted 1∶200 with the above BSA and Triton X-100 solution and incubated with the cells at room temperature for 60 min. FTIC-conjugated rabbit polyclonal antibody to mouse IgG in 1∶300 dilution was added to the cells for 60 min incubation at room temperature in the dark. The slides were viewed with an Olympus AX70 microscope (Melville, NY) equipped with a FITC filter.
All animal studies were carried out in accordance with the guidelines of the Institute for Animal Studies at the Albert Einstein College of Medicine. Human cervical carcinoma CasKi and human hepatocellular carcinoma Hep 3B2.1-7 cell lines were chosen as the tumor models based on its expression of E6 and HBx, respectively, and their tumorigenecity in nude mice. Six-week-old female Nu/Nu CD1 nude mice purchased from Charles River were injected into the right flank with 107 CaSki or Hep 3B2.1-7 cells in 0.1 ml DMEM medium containing 10% fetal calf serum. CasKi tumors began to appear around 60 days after injection, Hep 3B2.1-7 tumors-10 days post cell injection. For biodistribution of HBx-specific mAb, nude mice were inoculated with 107 A2058 human metastatic melanoma cells and 107 Hep 3B2.1-7 cells into the right and left flanks, respectively. Biodistribution and therapy experiments were initiated when the tumors reached 0.3–0.7 cm in diameter.
Immunohistochemical detection of HPV E6 protein in CasKi tumors
The tumors taken from CasKi tumor-bearing mice were fixed in 10% buffered formalin overnight, followed by placing in 70% ethanol. The paraffin-embedded tumor tissues were cut into 5 µm slides. The sections were deparaffinized in xylene and dehydrated in graded ethanol continuously, and pre-treated with citrate buffer (pH 6.0) at 100°C for 20 min to retrieve the antigen. The sections were treated with 3% hydrogen peroxide in methanol in order to block the endogenous peroxidase activity. IHC staining of the tumor tissue sections was then performed using Histostain®-Plus Kits Zymed® 2nd Generation LAB-SA Detection System (Invitrogen) according to the manufacturer's instruction. Mouse mAb C1P5 was used as primary antibody to detect E6 protein in the tumor tissues, and the negative control was incubated with 18B7 mAb instead of primary antibody under the same conditions. Other reagents used in IHC were supplied with the kit.
Western blot detection of HBx antigen in Hep 3B2.1-7 tumors
The Hep 3B2.1-7 tumors were homogenized on ice and western blot was performed as described above.
Biodistribution and scintigraphic imaging with 188Re-labeled mAbs
For biodistribution and scintigraphic imaging in CasKi or Hep 3B2.1-7 tumor-bearing mice, mice were divided into groups of three and injected IP with either 100 µCi of specific mAbs 188Re-C1P5 or 188Re-4H9 or with control mAb 188Re-18B7. Twenty-four hours post-injection mice were anesthetized with Isoflurane and scintigraphically imaged for 2 min on a Siemens gamma camera equipped with ICON image processing software. Forty eight hours post-injection mice were sacrificed and the tumors and muscle were removed, blotted from blood, weighted, counted in a gamma counter and percentage of injected dose per gram tissue and tumor to muscle ratios were calculated.
Therapy of CaSki and Hep 3B2.1-7 tumors in nude mice with 188Re-labeled mAbs
For therapeutic studies mice with tumors of 0.3–0.7 cm in diameter were randomized into the groups of six. For CasKi tumor-bearing mice, group # 1 was treated IP with 350 µCi 188Re-C1P5 mAb, group # 2–with matching amount (30 µg) “cold” C1P5 mAb, and group # 3 was left untreated. For RIT of Hep 3B2.1-7 tumor-bearing mice, group # 1 was given IP 240 µCi 188Re-4H9 mAb, group # 2–280 µCi, # 3–350 µCi, # 4–500 µCi, # 5–600 µCi of 188Re-4H9 mAb, # 6–30 µg “cold” 4H9 mAb and group # 7 was left untreated. Mice were observed for their well–being and tumor growth. The size of the tumor was measured every 3 days with calipers in three dimensions and the tumor volume was calculated as a product of three dimensions divided by 2. For histological analysis the tumors were removed from the mice at the completion of the experiments, fixed in buffered formalin, parafinized, cut into 5 µm slices and stained with hematoxylin and eosin (H&E).
Conceived and designed the experiments: AC ED XW HS RB. Performed the experiments: ED RB XW ER. Analyzed the data: AC ED XW. Contributed reagents/materials/analysis tools: ED RB. Wrote the paper: AC ED. Other: Suggested idea for the study: AC.
- 1. Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118: 3030–3044.DM Parkin2006The global health burden of infection-associated cancers in the year 2002.Int J Cancer11830303044
- 2. Cesarman E, Mesri EA (2007) Kaposi sarcoma-associated herpesvirus and other viruses in human lymphomagenesis. Curr Top Microbiol Immunol 312: 263–287.E. CesarmanEA Mesri2007Kaposi sarcoma-associated herpesvirus and other viruses in human lymphomagenesis.Curr Top Microbiol Immunol312263287
- 3. Jones EE, Wells SI (2006) Cervical cancer and human papillomaviruses: inactivation of retinoblastoma and other tumor suppressor pathways. Curr Mol Med 6: 795–808.EE JonesSI Wells2006Cervical cancer and human papillomaviruses: inactivation of retinoblastoma and other tumor suppressor pathways.Curr Mol Med6795808
- 4. El-Aneed A, Banoub J (2006) Proteomics in the diagnosis of hepatocellular carcinoma: focus on high risk hepatitis B and C patients. Anticancer Res 26: 3293–3300.A. El-AneedJ. Banoub2006Proteomics in the diagnosis of hepatocellular carcinoma: focus on high risk hepatitis B and C patients.Anticancer Res2632933300
- 5. Arbach H, Viglasky V, Lefeu F, Guinebretiere JM, Ramirez V, et al. (2006) Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol). J Virol 80: 845–853.H. ArbachV. ViglaskyF. LefeuJM GuinebretiereV. Ramirez2006Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol).J Virol80845853
- 6. Young LS, Murray PG (2003) Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22: 5108–5121.LS YoungPG Murray2003Epstein-Barr virus and oncogenesis: from latent genes to tumours.Oncogene2251085121
- 7. Mortreux F, Gabet A-S, Wattel E (2003) Molecular and cellular aspects of HTLV-1 associated leukemogenesis in vivo. Leukemia 17: 26–38.F. MortreuxA-S GabetE. Wattel2003Molecular and cellular aspects of HTLV-1 associated leukemogenesis in vivo.Leukemia172638
- 8. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108.DM ParkinF. BrayJ. FerlayP. Pisani2005Global cancer statistics, 2002.CA Cancer J Clin5574108
- 9. Sharkey RM, Goldenberg DM (2005) Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 46: Suppl 1115S–127S.RM SharkeyDM Goldenberg2005Perspectives on cancer therapy with radiolabeled monoclonal antibodies.J Nucl Med46Suppl 1115S127S
- 10. Milenic DE, Brady ED, Brechbiel MW (2004) Antibody-targeted radiation cancer therapy. Nature Rev Drug Discovery 3: 488–499.DE MilenicED BradyMW Brechbiel2004Antibody-targeted radiation cancer therapy.Nature Rev Drug Discovery3488499
- 11. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, et al. (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352: 441–449.MS KaminskiM. TuckJ. EstesA. KolstadCW Ross2005131I-tositumomab therapy as initial treatment for follicular lymphoma.N Engl J Med352441449
- 12. Dadachova E, Nakouzi A, Bryan RA, Casadevall A (2003) Ionizing radiation delivered by specific antibody in therapeutic against a fungal infection. Proc Natl Acad Sci 100: 10942–10947.E. DadachovaA. NakouziRA BryanA. Casadevall2003Ionizing radiation delivered by specific antibody in therapeutic against a fungal infection.Proc Natl Acad Sci1001094210947
- 13. Dadachova E, Casadevall A (2006) Treatment of infection with radiolabeled antibodies. Q J Nucl Med Mol Imaging 50: 193–204.E. DadachovaA. Casadevall2006Treatment of infection with radiolabeled antibodies.Q J Nucl Med Mol Imaging50193204
- 14. Dadachova E, Patel MC, Toussi S, Apostolidis C, Morgenstern A, et al. (2006) Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Medicine 3: e427.E. DadachovaMC PatelS. ToussiC. ApostolidisA. Morgenstern2006Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins.PLoS Medicine3e427
- 15. Casadevall A, Goldstein H, Dadachova E (2007) Targeting viruses-harboring host cells with radiolabeled antibodies. Expert Opinion Biol Ther 7: 595–597.A. CasadevallH. GoldsteinE. Dadachova2007Targeting viruses-harboring host cells with radiolabeled antibodies.Expert Opinion Biol Ther7595597
- 16. Dadachova E, Wang X-G, Casadevall A (2007) Targeting the virus with radioimmunotherapy in virus-associated cancer. Cancer Biother Radiopharm 22: 303–308.E. DadachovaX-G WangA. Casadevall2007Targeting the virus with radioimmunotherapy in virus-associated cancer.Cancer Biother Radiopharm22303308
- 17. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, et al. (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 87: 796–802.FX BoschMM ManosN. MunozM. ShermanAM Jansen1995Prevalence of human papillomavirus in cervical cancer: a worldwide perspective.J Natl Cancer Inst87796802
- 18. Schlecht NF (2005) Prognostic value of human papillomavirus in the survival of head and neck cancer patients: an overview of the evidence. Oncol Rep 14: 1239–1247.NF Schlecht2005Prognostic value of human papillomavirus in the survival of head and neck cancer patients: an overview of the evidence.Oncol Rep1412391247
- 19. Kehmeier E, Rühl H, Voland B, Stöppler MC, Androphy E, et al. (2002) Cellular steady-state levels of “high risk” but not “low risk” human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities. Virology 299: 72–87.E. KehmeierH. RühlB. VolandMC StöpplerE. Androphy2002Cellular steady-state levels of “high risk” but not “low risk” human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities.Virology2997287
- 20. Oh KJ, Kalinina A, Wang J, Nakayama K, Nakayama KI, et al. (2004) The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin 1- and Skp2-containing E3 ligase. J Virol 78: 5338–5346.KJ OhA. KalininaJ. WangK. NakayamaKI Nakayama2004The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin 1- and Skp2-containing E3 ligase.J Virol7853385346
- 21. Hwang GY, Lin CY, Huang LM, Wang YH, Wang JC, et al. (2003) Detection of the Hepatitis B Virus X Protein (HBx) Antigen and Anti-HBx Antibodies in Cases of Human Hepatocellular Carcinoma. J Clinical Microbiol 41: 5598–5603.GY HwangCY LinLM HuangYH WangJC Wang2003Detection of the Hepatitis B Virus X Protein (HBx) Antigen and Anti-HBx Antibodies in Cases of Human Hepatocellular Carcinoma.J Clinical Microbiol4155985603
- 22. Lupberger J, Hildt E (2007) Hepatitis B virus-induced oncogenesis. World J Gastroenterol 13: 74–81.J. LupbergerE. Hildt2007Hepatitis B virus-induced oncogenesis.World J Gastroenterol137481
- 23. Reifenberg K, Wilts H, Löhler J, Nusser P, Hanano R, et al. (1999) The Hepatitics B virus X protein transactivates viral core gene expression in vivo. J. Virol. 73: 10399–10405.K. ReifenbergH. WiltsJ. LöhlerP. NusserR. Hanano1999The Hepatitics B virus X protein transactivates viral core gene expression in vivo.J. Virol.731039910405
- 24. Chen FM, Taylor CR, Epstein AL (1989) Tumor necrosis treatment of ME-180 human cervical carcinoma model with 131I-labeled TNT-1 monoclonal antibody. Cancer Res 49: 4578–4585.FM ChenCR TaylorAL Epstein1989Tumor necrosis treatment of ME-180 human cervical carcinoma model with 131I-labeled TNT-1 monoclonal antibody.Cancer Res4945784585
- 25. Yang JS, Li WJ, Zhou GM, Jin XD, Xia JG, et al. (2005) Comparative study on radiosensitivity of various tumor cells and human normal liver cells. World J Gastroenterol 11: 4098–4101.JS YangWJ LiGM ZhouXD JinJG Xia2005Comparative study on radiosensitivity of various tumor cells and human normal liver cells.World J Gastroenterol1140984101
- 26. Sharkey RM, Blumenthal RD, Behr TM, Wong GY, Haywood L, et al. (1997) Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma. Int J Cancer 72: 477–485.RM SharkeyRD BlumenthalTM BehrGY WongL. Haywood1997Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma.Int J Cancer72477485
- 27. Schweitzer AD, Rakesh V, Revskaya E, Datta A, Casadevall A, et al. (2007) Computational model predicts effective delivery of 188-Re-labeled melanin-binding antibody to the metastatic melanoma tumors with wide range of melanin concentrations. Melanoma Res 17: 291–303.AD SchweitzerV. RakeshE. RevskayaA. DattaA. Casadevall2007Computational model predicts effective delivery of 188-Re-labeled melanin-binding antibody to the metastatic melanoma tumors with wide range of melanin concentrations.Melanoma Res17291303
- 28. Casadevall A, Mukherjee J, Devi SJ, Schneerson R, Robbins JB, et al. (1992) Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infec Dis 165: 1086–1093.A. CasadevallJ. MukherjeeSJ DeviR. SchneersonJB Robbins1992Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.J Infec Dis16510861093